Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934531 | 0.86 | TRPV1 (0.54) | KMT2ATPSAB1HPGDALDH1A1KDM4E | |
| SCHEMBL660986 | 0.86 | KMT2A (0.62) | KMT2ALMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL21648724 | 0.86 | EPHX2 (0.51) | LMNATPSAB1HPGDALDH1A1 | |
| SCHEMBL13024401 | 0.86 | TPSAB1 (0.50) | LMNATPSAB1CA1CA2HPGD | |
| SCHEMBL13181415 | 0.86 | KMT2A (0.61) | KMT2ATPSAB1HPGDALDH1A1 | |
| SCHEMBL933833 | 0.84 | CA12 (0.49) | LMNATPSAB1CA12CA1CA2 | |
| SCHEMBL18134836 | 0.84 | CYP3A4 (0.65) | KMT2ALMNATPSAB1HPGDALDH1A1 | |
| SCHEMBL15651444 | 0.84 | PPID (0.54) | TPSAB1HPGDALDH1A1 | |
| SCHEMBL14107294 | 0.84 | TPSAB1 (0.48) | LMNATPSAB1HPGDALDH1A1 | |
| SCHEMBL1709315 | 0.84 | HPGD (0.70) | KMT2ACA12CA1CA2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160252518-A1 | QUATERNARY AMINE CONTAINING ISOBARIC TAG FOR QUANTITATIVE GLYCAN PROFILING | THE JOHNS HOPKINS UNIVERSITY | 2016-09-01 | — | — | US | disclosed |
| US-8969571-B2 | Biphenyl derivatives | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130150404-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8247564-B2 | Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8242135-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8143277-B2 | Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110312994-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8008278-B2 | Diarylmethyl and related compounds | THERAVANCE, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7893256-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7358244-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7355046-B2 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7345175-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345060-B2 | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20080015220-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-01-17 | — | — | US | disclosed |
| US-7317102-B2 | Diarylmethyl and related compounds | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20070276003-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-29 | — | — | US | disclosed |
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070088054-A1 | e.g. 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethyl}amino)-hexyl]oxy}butyl)benzenesulfonamide; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity; bronchodilator agent; pulmonary disorders: chronic obstructive pulmonary disease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-04-19 | — | — | US | disclosed |
| US-20070037984-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037984-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | ADRB2, ADRA2B, ADRB1 | KMT2A 566/4885LMNA 2750/4885TPSAB1 404/4885 |
| US-20070088054-A1 | e.g. 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethyl}amino)-hexyl]oxy}butyl)benzenesulfonamide; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity; bronchodilator agent; pulmonary disorders: chronic obstructive pulmonary disease; asthma | ADRB2, ADRB3, ADRB1 | KMT2A 1260/4885LMNA 3405/4885TPSAB1 281/4885 |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | KMT2A 1190/4885LMNA 3024/4885TPSAB1 398/4885 |
| US-20070276003-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | KMT2A 770/4885LMNA 2398/4885TPSAB1 316/4885 |
| US-20080015220-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | KMT2A 770/4885LMNA 2398/4885TPSAB1 316/4885 |
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | KMT2A 770/4885LMNA 2398/4885TPSAB1 316/4885 |
| US-20130150404-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | KMT2A 1204/4885LMNA 3053/4885TPSAB1 408/4885 |
| US-20110312994-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | KMT2A 1190/4885LMNA 3024/4885TPSAB1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.